Dr Oertelt-Prigione continues:
What we’re seeing is — of the first 10 to 15 publications, which mostly included trials testing the drugs hydroxychloroquine and remdesivir — you’re lucky if you find out how many women and men participated in the trial. There’s no disaggregated analysis. We don’t know anything about risk factors. We don’t know anything about unwanted side effects — if there were differences or not.
So far so Invisible Women. And remember: “The immune system is also thought to be behind sex-specific responses to vaccines: women develop higher antibody responses and have more frequent and severe adverse reactions to vaccines,19 and a 2014 paper proposed developing male and female versions of influenza vaccines.” (IW, p.199)
But wait, there’s more
I think the approach here is what unfortunately happens in an emergency — we’re trying to go as fast as possible and looking into sex differences is perceived as something that is just going to cost us time. In any case, this was what was happening before (Covid-19) as well.
It’s also a race that has financial costs. Being the first one to produce a vaccine can make or break a pharmaceutical company, especially if it’s a smaller one. And considering sex differences is simply not an issue that has a large enough lobby, which is ironic if you consider that it affects the entire population.